Most Read Articles
3 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 3 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

COVID-19 mortality higher among multiple myeloma patients

12 Nov 2020

Multiple myeloma (MM) patients hospitalized for the novel coronavirus disease (COVID-19) suffer from an excess risk of death, a recent study has found.

In the present Spanish retrospective case series, a total of 167 MM patients with COVID-19 (median age, 71 years; 57 percent male) were included. Outcomes were assessed using a modified version of the International Myeloma Society questionnaire and were compared against 167 randomly selected age- and sex-matched controls, who were also positive for COVID-19 but had no cancer.

Fifty-six MM patients died during hospital admission, corresponding to a mortality rate of 34 percent. This was 50-percent greater compared to the 23-percent hospital death rate in noncancer controls. Conversely, the rate of hospital discharge was 10-percent greater in controls than in MM patients (76 percent vs 66 percent).

Mortality was almost doubled in males than in females (41 percent vs 24 percent) and increased with age. Rates were 38–39 percent in those aged ≥60 years, while the corresponding value was nearly halved in younger comparators. MM featuressuch as an active disease at the time of COVID-19 admission and main immunoglobulin componentalso affected mortality rates.

Logistic regression analysis confirmed that the male sex (odds ratio [OR[, 3.8, 95 percent confidence interval [CI], 1.7–8.4; p=0.001) and age >65 years (OR, 3.0, 95 percent CI, 1.4–8.4; p=0.006) were significant risk factors for COVID-19 mortality in MM patients.

In addition, having active or progressive disease (OR, 4.6, 95 percent CI, 1.9–11.3; p<0.001) and comorbid renal disease (OR, 2.7, 95 percent CI, 1.2–6.0; p=0.017) at admission likewise worsened survival. None of the MM features and treatment variables, such as monoclonal component and duration of diagnosis, significantly impacted COVID-19 mortality.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 3 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.